Drug delivery for treatment of inner ear disease: current state of knowledge
- PMID: 19952751
- PMCID: PMC2836414
- DOI: 10.1097/AUD.0b013e3181c351f2
Drug delivery for treatment of inner ear disease: current state of knowledge
Abstract
Delivery of medications to the inner ear has been an area of considerable growth in both the research and clinical realms during the past several decades. Systemic delivery of medication destined for treatment of the inner ear is the foundation on which newer delivery techniques have been developed. Because of systemic side effects, investigators and clinicians have begun developing and using techniques to deliver therapeutic agents locally. Alongside the now commonplace use of intratympanic gentamicin for Meniere's disease and the emerging use of intratympanic steroids for sudden sensorineural hearing loss, novel technologies, such as hydrogels and nanoparticles, are being explored. At the horizon of inner ear drug-delivery techniques, intracochlear devices that leverage recent advances in microsystems technology are being developed to apply medications directly into the inner ear. Potential uses for such devices include neurotrophic factor and steroid delivery with cochlear implantation, RNA interference technologies, and stem-cell therapy. The historical, current, and future delivery techniques and uses of drug delivery for treatment of inner ear disease serve as the basis for this review.
Comment in
-
Guest editorial: drug delivery for treatment of inner ear disease: current state of knowledge.Ear Hear. 2010 Apr;31(2):155. doi: 10.1097/AUD.0b013e3181d43cc6. Ear Hear. 2010. PMID: 20215911 No abstract available.
Similar articles
-
Guest editorial: drug delivery for treatment of inner ear disease: current state of knowledge.Ear Hear. 2010 Apr;31(2):155. doi: 10.1097/AUD.0b013e3181d43cc6. Ear Hear. 2010. PMID: 20215911 No abstract available.
-
A state-of-the-art analysis of pharmacological delivery and artificial intelligence techniques for inner ear disease treatment.Environ Res. 2023 Nov 1;236(Pt 1):116457. doi: 10.1016/j.envres.2023.116457. Epub 2023 Jul 15. Environ Res. 2023. PMID: 37459944
-
The role of intracochlear drug delivery devices in the management of inner ear disease.Expert Opin Drug Deliv. 2015 Mar;12(3):465-79. doi: 10.1517/17425247.2015.974548. Epub 2014 Oct 27. Expert Opin Drug Deliv. 2015. PMID: 25347140 Review.
-
[Intratympanic drug delivery for the treatment of inner ear diseases].Acta Otorrinolaringol Esp. 2010 May-Jun;61(3):225-32. doi: 10.1016/j.otorri.2009.03.008. Epub 2009 Sep 18. Acta Otorrinolaringol Esp. 2010. PMID: 20452879 Review. Spanish.
-
A regulated delivery system for inner ear drug application.J Control Release. 2013 Mar 28;166(3):268-76. doi: 10.1016/j.jconrel.2012.12.031. Epub 2013 Jan 8. J Control Release. 2013. PMID: 23313113
Cited by
-
Promising Applications of Nanoparticles in the Treatment of Hearing Loss.Front Cell Dev Biol. 2021 Oct 7;9:750185. doi: 10.3389/fcell.2021.750185. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34692703 Free PMC article. Review.
-
Ultrastructural Changes Associated With the Enhanced Permeability of the Round Window Membrane Mediated by Ultrasound Microbubbles.Front Pharmacol. 2020 Jan 28;10:1580. doi: 10.3389/fphar.2019.01580. eCollection 2019. Front Pharmacol. 2020. PMID: 32047431 Free PMC article.
-
In-vitro perforation of the round window membrane via direct 3-D printed microneedles.Biomed Microdevices. 2018 Jun 8;20(2):47. doi: 10.1007/s10544-018-0287-3. Biomed Microdevices. 2018. PMID: 29884927 Free PMC article.
-
Prevention and restoration of hearing loss associated with the use of cisplatin.Biomed Res Int. 2014;2014:925485. doi: 10.1155/2014/925485. Epub 2014 Jul 22. Biomed Res Int. 2014. PMID: 25140325 Free PMC article. Review.
-
Reducing Auditory Nerve Excitability by Acute Antagonism of Ca2+-Permeable AMPA Receptors.Front Synaptic Neurosci. 2021 Jul 5;13:680621. doi: 10.3389/fnsyn.2021.680621. eCollection 2021. Front Synaptic Neurosci. 2021. PMID: 34290596 Free PMC article.
References
-
- Abou-Halawa AS, Poe DS. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Meniere's disease. Otol Neurotol. 2002;23:494–502. - PubMed
-
- Alzamil KS, Linthicum FH., Jr. Extraneous round window membranes and plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol. 2000;109:30–32. - PubMed
-
- Battista RA. Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2005;132:902–905. - PubMed
-
- Batts SA, Raphael Y. Transdifferentiation and its applicability for inner ear therapy. Hear Res. 2007;227:41–47. - PubMed
-
- Beck C, Schmidt CL. 10 years of experience with intratympanally applied streptomycin (gentamycin) in the therapy of Morbus Meniere. Arch Otorhinolaryngol. 1978;221:149–152. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous